We were honoured to recently host Professor Samuel Haryono from the Siloam Group Indonesia during his visit to the Digistain research lab at Imperial College London.
This visit provided an incredible opportunity to showcase some of the innovative research we’re working on to further advance the Digistain assay and make recurrence-risk testing more accessible.
With Indonesia’s population of over 270 million people, improving access to recurrence-risk testing is more critical than ever. We had the chance to discuss this, our shared commitment to improving patient outcomes and our vision for advancing cancer care through technology.
We look forward to fostering even more connections like these as we continue striving to support access to recurrence-risk testing.
